VisiRose, Inc.

About VisiRose, Inc.

VisiRose, Inc. is a startup biotechnology company focused on pioneering a global revolution to protect and restore vision. Through innovative research and technology, VisiRose aims to transform lives by offering revolutionary treatments for eye diseases and infections, such as infectious keratitis, using bioactive synthetic small molecule rose bengal. The company is a collaboration between the University of Miami, Provectus Biopharmaceuticals, and the Bascom Palmer Eye Institute.

Products & Services

Rose Bengal & Photodynamic Therapy:Revolutionary treatments for infectious keratitis and other eye diseases using pharmaceutical-grade rose bengal API.

Specialties

Ocular research Vision restoration Rose Bengal-based treatments Photodynamic therapy Infectious keratitis treatment

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Seed T: - FT: Seed	A: 3000000 MR: - FA: $3 million FAN: 3000000	D: 2025-01-14 FD: 2025-01-14	-

Seed Latest

2025-01-14

$3.0M

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

E

Ed Pershing

Chairman of the Board

D

Dominic Rodrigues

Acting Chief Executive Officer; Director

H

Heather Raines

Acting Chief Financial Officer

J

John Lacey, III, M.D

Director

W

Webster Bailey

Director

View 2 more team members with Pro

Unlock Full Team Directory

Recent News

VisiRose, Inc. Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised